Jose Carpio, MD
Allergy & Immunology · Miami, FLNPI 1881682847
Payments from drug & device makers
Across 594 payments — averaging $6046.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1.3M
- Eli Lilly$1M
- Organon$421K
- AbbVie$248K
- AstraZeneca$195K
- Amgen$193K
- plus $170K from 23 others
Across 4 payments — averaging $117.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$340
- Eli Lilly$128
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 303 | $1,332,781 |
| Eli Lilly | 13 | $1,030,751 |
| Organon | 28 | $420,596 |
| AbbVie | 20 | $248,283 |
| AstraZeneca | 48 | $195,386 |
| Amgen | 11 | $193,492 |
| Eisai Inc. | 45 | $61,560 |
| Lupin Inc. | 1 | $47,230 |
| Cipla USA Inc. | 6 | $18,074 |
| Dermira, Inc. | 1 | $12,500 |
| Teva Pharmaceuticals USA, Inc. | 22 | $11,395 |
| Biohaven Pharmaceuticals, Inc. | 1 | $8,250 |
| Bayer | 4 | $4,036 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $2,500 |
| Boehringer Ingelheim | 1 | $2,230 |
| Regeneron Healthcare Solutions, Inc. | 33 | $936 |
| Sanofi | 15 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $261 |
| Octapharma USA, Inc. | 3 | $210 |
| Pfizer | 12 | $202 |
| CSL Behring | 5 | $112 |
| Alk-abello, Inc | 1 | $95 |
| Optinose US, Inc. | 3 | $56 |
| Novartis | 2 | $52 |
| Genentech USA, Inc. | 2 | $40 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
How this compares
$3,591,445 in reported general payments places this provider in the 95th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Miami
- Ileana RodicioMiami$3.8M
- Nina RamirezMiami$833K
- Vicente ChavarriaMiami$828K
- Gary KleinerMiami$149K
- Neil GershmanMiami$18K
- Viviana SirvenMiami$14K
- Jaime LandmanAventura$3.9M
- Michael KohenDaytona Beach$3.6M
- Thomas CasaleTampa$1.7M
- Dennis LedfordTampa$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.